NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
Clinical Trials
157 trialsNCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT06169202 2023-12-13
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
China Medical University, China
Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT05081687 2023-10-11
BRAZIL-TNT
Hospital Israelita Albert Einstein
Phase 3 Unknown
NCT04324307 2023-09-01
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Phase 1/2 Unknown
NCT04169347 2023-07-27
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
Phase 2 Unknown
NCT05731518 2023-07-14
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT05832398 2023-06-28
Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase NA Unknown
NCT04189055 2023-06-12
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Phase 2 Unknown
NCT05160896 2023-06-08
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05868317 2023-05-22
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Phase 2 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05750290 2023-03-01
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05732129 2023-02-24
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Fudan University
Phase 2 Unknown
NCT05669807 2023-01-03
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05643677 2022-12-09
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05235542 2022-08-11
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Akeso
Phase 1/2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05160727 2021-12-20
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT04924192 2021-09-21
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT03603834 2021-09-01
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Khon Kaen University
Phase 2 Unknown
NCT03126071 2021-08-30
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT05018182 2021-08-24
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
West China Hospital
Phase 2 Unknown
NCT04985201 2021-08-09
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04358354 2021-07-19
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT03751176 2021-06-30
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04915807 2021-06-07
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Unknown
NCT03484195 2021-04-19
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer
China Medical University, China
Phase 2 Unknown
NCT03487939 2021-04-19
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
China Medical University, China
Phase 2 Unknown
NCT03484221 2021-04-14
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
China Medical University, China
Phase 2 Unknown
NCT04393584 2021-04-13
RusGCG-01
Blokhin's Russian Cancer Research Center
Phase 2/3 Unknown
NCT04442984 2021-04-13
IRIGA
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT03403101 2021-04-09
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT04833036 2021-04-06
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
Phase 2 Unknown
NCT04789941 2021-03-10
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix
Assiut University
Phase 2 Unknown
NCT02171325 2021-02-03
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT04486651 2021-01-28
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT04689100 2020-12-30
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Shanghai JMT-Bio Inc.
Phase 1 Unknown
NCT04668976 2020-12-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
Phase 2 Unknown
NCT03608046 2020-10-22
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT04358341 2020-08-24
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT04499586 2020-08-05
A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
Fudan University
Phase 2 Unknown